Project goal is to develop a prototype active immunotherapy to complement directly acting antiviral drugs in treatment of chronic hepatitis C, which would target and eliminate HCV-infected cells, specifically malignant (transformed) hepatocytes and lymphocytes. The immunotherapy will be based on a conserved HCV antigen nucleocapsid (Core) protein and tumor-associated antigen involved in the early events in hepatocarcinogenesis, human telomerase reverse transcriptase, presented by synthetic genes (HCV/TERT-DNA).
|Effective start/end date||1/12/18 → 28/02/21|
- Latvian Council of Science: €200,000.00
- hepatitis C
- hepatocellular carcinoma
- non-Hodgkin's B-cell lymphoma
- DNA vaccine
- TLR ligand
- checkpoint inhibitor
- mouse model
Field of Science
- 3.3 Health sciences
Smart Specialization Area
- Biomedicine, medical technologies and biotechnology
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.